Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Biogen Inc shares valued at $480,508 were sold by Singhal Priya on May 19 ’25. At $126.25 per share, Singhal Priya sold 3,806 shares. The insider’s holdings dropped to 5,427 shares worth approximately $0.69 million following the completion of this transaction.
Also, Singhal Priya purchased 3,806 shares, netting a total of over 480,508 in proceeds.
Before that, DORSA CAROLINE had added 1,235 shares to its account. In a trade valued at $151,559, the Director bought Biogen Inc shares for $122.72 each. Upon closing the transaction, the insider’s holdings increased to 1,235 shares, worth approximately $3.52 million.
As published in a research note from HSBC Securities on April 28, 2025, Biogen Inc [BIIB] has been rated down from a Buy to a Hold and the price target has been revised to $118. Analysts at Argus downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in early April. As of February 11, 2025, Bernstein has initiated its “Mkt perform” rating for BIIB. Earlier on January 02, 2025, Piper Sandler downgraded its rating. Their new recommendation was “a Neutral” for BIIB stock which previously was a “an Overweight”.
Analyzing BIIB Stock Performance
During the last five days, there has been a surge of approximately 2.10%. Over the course of the year, Biogen Inc shares have dropped approximately -17.41%. Shares of the company reached a 52-week high of $157.09 on 03/10/25 and a 52-week low of $110.04 on 04/09/25.
Support And Resistance Levels for Biogen Inc (BIIB)
According to the 24-hour chart, there is a support level at 125.41, which, if violated, would cause prices to drop to 124.52. In the upper region, resistance lies at 127.13. The next price resistance is at 127.96. RSI (Relative Strength Index) is 53.97 on the 14-day chart, showing neutral technical sentiment.
